Last reviewed · How we verify
Astion Pharma A/S — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
2 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| ASF1057 | ASF1057 | phase 3 |
Therapeutic area mix
- Dermatology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- Al-Azhar University · 1 shared drug class
- All India Institute of Medical Sciences, Bhubaneswar · 1 shared drug class
- Apotex Inc. · 1 shared drug class
- Astellas Pharma Inc · 1 shared drug class
- AstraZeneca · 1 shared drug class
- Aswan University Hospital · 1 shared drug class
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Astion Pharma A/S:
- Astion Pharma A/S pipeline updates — RSS
- Astion Pharma A/S pipeline updates — Atom
- Astion Pharma A/S pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Astion Pharma A/S — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/astion-pharma-a-s. Accessed 2026-06-10.